%0 Journal Article
%T Evaluation of ¦Á-synuclein and apolipoprotein E as potential biomarkers in cerebrospinal fluid to monitor pharmacotherapeutic efficacy in dopamine dictated disease states of Parkinson¡¯s disease and schizophrenia
%A Ashish Kumar Gupta
%A Domada Ratna Kumar
%A Gururao Hariprasad
%A Manjari Tripathi
%A Mohd Imran Khan
%A Rakesh Kumar Chadda
%A Rashmi Ramachandran
%A Rishab Gupta
%A Ruchika Pokhriyal
%A Uddipan Das
%A Vinay Goyal
%J Archive of "Neuropsychiatric Disease and Treatment".
%D 2019
%R 10.2147/NDT.S205550
%X Dopamine plays an important role in the disease pathology of Parkinson¡¯s disease and schizophrenia. These two neuropsychiatric disorders represent disease end points of the dopaminergic spectrum where Parkinson¡¯s disease represents dopamine deficit and schizophrenia represents dopamine hyperactivity in the mid-brain. Therefore, current treatment strategies aim to restore normal dopamine levels. However, during treatment patients develop adverse effects due to overshooting of physiological levels of dopamine leading to psychosis in Parkinson¡¯s disease, and extrapyramidal symptoms in schizophrenia. Absence of any laboratory tests hampers modulation of pharmacotherapy. Apolipoprotein E and ¦Á-synuclein have an important role in the neuropathology of these two diseases. The objective of this study was to evaluate cerebrospinal fluid (CSF) concentrations of apolipoprotein E and ¦Á-synuclein in patients with these two diseases so that they may serve as biomarkers to monitor therapy in Parkinson¡¯s disease and schizophrenia
%K cerebrospinal fluid
%K Parkinson¡¯s disease
%K schizophrenia
%K dopamine
%K apolipoprotein E
%K ¦Á-synuclein
%K biomarkers
%K treatment monitoring
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6650621/